4D Pharma

16 articles with 4D Pharma

• 4D Pharma Collaborates With MSD to Develop Live Biotherapeutics for Vaccines

  10/8/2019

  4D pharma plc announces that the Company has entered into a research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

• 

  4D Pharma and Merck Team to Develop Microbiome-based Vaccines

  10/8/2019

  Under the terms of the deal, 4D will use its proprietary MicroRx platform with Merck’s expertise in novel vaccine development and commercialization to discover and develop Live Biotherapeutics as vaccines in up to three currently undisclosed indications.

• 4D pharma plc: Publication of Data on Neurodegenerative Disease Programmes

  9/23/2019

  4D pharma announces the publication of data highlighting the neuroprotective properties of MRx0005 and MRx0029

• 4D pharma plc: Oncology Programmes Update

  7/25/2019

  Second-generation Live Biotherapeutic Identified and Mechanistic Data on MRx0518 and MRx1299 Presented

• 4D pharma plc Commences Phase I/II Asthma Trial

  7/8/2019

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutics, announces an update on its lead Live Biotherapeutic candidate for asthma, MRx-4DP0004.

• 4D Presents MRx0518 Combination Study at ASCO 2019, Chicago, USA

  6/3/2019

  4D pharma plc announces the presentation of a poster detailing its Phase I/II clinical study of MRx0518 combined with KEYTRUDA® in patients with solid tumours who have failed prior anti-PD-1 therapy at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago, USA.

• 4D Presents Phase Ib Clinical Data on Thetanix®

  5/16/2019

  4D pharma plc, a pharmaceutical company focusing on the development of Live Biotherapeutics, announced that data from the completed Phase Ib clinical study of Thetanix® for the treatment of Crohn's disease will be presented on 18 May in a poster session at the 2019 Digestive Disease Week meeting in San Diego.

• 4D Announces Participation in Neuro4D Conference, Frankfurt, Germany

  5/13/2019

  4D pharma plc announces its participation in the Neuro4D conference, Frankfurt, Germany, 13-14 May, 2019.

• 4D Pharma Clinical Update - MRx0518 Oncology Programmes

  4/29/2019

  4D pharma plc announces an update on the clinical progress of its lead oncology Live Biotherapeutic MRx0518.

• 4D Pharma Announces Publication of Data Highlighting Immuno-Stimulatory Properties of MRx0518

  1/29/2019

  4D Pharma plc announces the publication of a paper outlining the mechanism and strong immuno-stimulatory effects of MRx0518.

• 4D pharma plc: Appointment of Independent Non-Executive Directors

  1/8/2019

  4D pharma plc today announces the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as independent Non-Executive Directors with immediate effect.

• MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors

  1/7/2019

  The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.

• 4D pharma and MD Anderson Cancer Center to Evaluate Live Biotherapeutics in Solid Tumours

  1/7/2019

  4D pharma plc and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings.

• 4D Presents at IHMC 2018

  6/27/2018

  Dr. Alex Stevenson, has spoken at the International Human Microbiome Consortium (IHMC) 2018 on the importance of function in the development of live biotherapeutics.

• 4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours

  6/7/2018

  4D pharma plc is a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products

• Manchester's 4D Pharma Reels In $29 Million

  6/26/2014